文献速递眼底病与葡萄膜炎

在AREDS补充剂中添加叶黄素/玉米黄素和ω-3脂肪酸对年龄相关性黄斑变性进展的长期结局:AREDS2报告28

Long-term Outcomes of Adding Lutein/Zeaxanthin and ω-3 Fatty Acids to the AREDS Supplements on Age-Related Macular Degeneration Progression: AREDS2 Report 28.
PubMed 文献 · JAMA Ophthalmol · 2022-01-01

本研究为AREDS2临床试验的多中心流行病学随访研究,纳入3882名参与者(6351只眼),随访10年。结果显示,随机分配至β-胡萝卜素组者肺癌OR为1.82(95%CI 1.06-3.12;P=.02),叶黄素/玉米黄素组OR为1.15(95%CI 0.79-1.66;P=.46)。叶黄素/玉米黄素与无叶黄素/玉米黄素相比,晚期AMD进展HR为0.91(95%CI 0.84-0.99;P=.02);在随机分配至β-胡萝卜素者中,叶黄素/玉米黄素HR为0.80(95%CI 0.68-0.92;P=.002)。

要点

  • β-胡萝卜素使用使肺癌风险近乎翻倍(OR 1.82),叶黄素/玉米黄素无统计学显著风险增加(OR 1.15)。
  • 叶黄素/玉米黄素与晚期AMD进展风险降低相关(HR 0.91),在β-胡萝卜素使用者中更明显(HR 0.80)。
  • ω-3脂肪酸、低剂量锌与高剂量锌、无β-胡萝卜素与β-胡萝卜素对晚期AMD进展均无显著差异。

核心结论

  • 长期流行病学随访结果表明,叶黄素/玉米黄素是AREDS2补充剂中β-胡萝卜素的适当替代品。
  • β-胡萝卜素使用使肺癌风险近乎翻倍,而叶黄素/玉米黄素无统计学显著风险增加。
  • 与β-胡萝卜素相比,叶黄素/玉米黄素对晚期AMD进展具有潜在有益关联。

研究设计与样本

  • 本研究为AREDS2临床试验的多中心流行病学随访研究,于2012年12月1日至2018年12月31日进行。
  • 纳入双侧或单侧中期AMD参与者,在临床试验结束后额外随访5年,共纳入3882名参与者(平均[SD]基线年龄72.0[7.7]岁;2240名女性[57.7%])和6351只眼。
  • 临床试验期间,参与者主要随机分配至叶黄素/玉米黄素和/或ω-3脂肪酸或安慰剂,次要随机分配至无β-胡萝卜素 vs β-胡萝卜素以及低剂量 vs 高剂量锌;随访研究中所有参与者接受含叶黄素/玉米黄素、维生素C和E、锌加铜的AREDS2补充剂。
  • 结局通过6个月一次的电话访视评估,AMD进展和肺癌分析分别采用比例风险回归和逻辑回归。
  • 主要结局为自报肺癌和晚期AMD,并经医疗记录验证。

主要发现

  • 10年时,随机分配至β-胡萝卜素者肺癌OR为1.82(95%CI 1.06-3.12;P=.02),叶黄素/玉米黄素者OR为1.15(95%CI 0.79-1.66;P=.46)。
  • 叶黄素/玉米黄素与无叶黄素/玉米黄素相比,晚期AMD进展HR为0.91(95%CI 0.84-0.99;P=.02);ω-3脂肪酸与无ω-3脂肪酸相比HR为1.01(95%CI 0.93-1.09;P=.91)。
  • 在随机分配至β-胡萝卜素者中,叶黄素/玉米黄素主效应分析HR为0.80(95%CI 0.68-0.92;P=.002);叶黄素/玉米黄素 vs β-胡萝卜素直接分析显示晚期AMD的HR为0.85(95%CI 0.73-0.98;P=.02)。
  • 低剂量 vs 高剂量锌的HR为1.04(95%CI 0.94-1.14;P=.49),无β-胡萝卜素 vs β-胡萝卜素的HR为1.04(95%CI 0.94-1.15;P=.48)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: After the Age-Related Eye Disease Study 2 (AREDS2) study, the beta carotene component was replaced by lutein/zeaxanthin for the development of the revised AREDS supplement. However, it is unknown if the increased risk of lung cancer observed in those assigned beta carotene persists beyond the conclusion of the AREDS2 trial and if there is a benefit of adding lutein/zeaxanthin to the original AREDS supplement that can be observed with long-term follow-up. OBJECTIVE: To assess 10-year risk of developing lung cancer and late age-related macular degeneration (AMD). DESIGN, SETTING, AND PARTICIPANTS: This was a multicenter epidemiologic follow-up study of the AREDS2 clinical trial, conducted from December 1, 2012, to December 31, 2018. Included in the analysis were participants with bilateral or unilateral intermediate AMD for an additional 5 years after clinical trial. Eyes/participants were censored at the time of late AMD development, death, or loss to follow-up. Data were analyzed from November 2019 to March 2022. INTERVENTIONS: During the clinical trial, participants were randomly assigned primarily to lutein/zeaxanthin and/or ω-3 fatty acids or placebo and secondarily to no beta carotene vs beta carotene and low vs high doses of zinc. In the epidemiologic follow-up study, all participants received AREDS2 supplements with lutein/zeaxanthin, vitamins C and E, and zinc plus copper. Outcomes were assessed at 6-month telephone calls. Analyses of AMD progression and lung cancer development were conducted using proportional hazards regression and logistic regression, respectively. MAIN OUTCOMES AND MEASURES: Self-reported lung cancer and late AMD validated with medical records. RESULTS: This study included 3882 participants (mean [SD] baseline age, 72.0 [7.7] years; 2240 women [57.7%]) and 6351 eyes. At 10 years, the odds ratio (OR) of having lung cancer was 1.82 (95% CI, 1.06-3.12; P = .02) for those randomly assigned to beta carotene and 1.15 (95% CI, 0.79-1.66; P = .46) for lutein/zeaxanthin. The hazard ratio (HR) for progression to late AMD comparing lutein/zeaxanthin with no lutein/zeaxanthin was 0.91 (95% CI, 0.84-0.99; P = .02) and comparing ω-3 fatty acids with no ω-3 fatty acids was 1.01 (95% CI, 0.93-1.09; P = .91). When the lutein/zeaxanthin main effects analysis was restricted to those randomly assigned to beta carotene, the HR was 0.80 (95% CI, 0.68-0.92; P = .002). A direct analysis of lutein/zeaxanthin vs beta carotene showed the HR for late AMD was 0.85 (95% CI, 0.73-0.98; P = .02). The HR for low vs high zinc was 1.04 (95% CI, 0.94-1.14; P = .49), and the HR for no beta carotene vs beta carotene was 1.04 (95% CI, 0.94-1.15; P = .48). CONCLUSIONS AND RELEVANCE: Results of this long-term epidemiologic follow-up study of the AREDS2 cohort suggest that lutein/zeaxanthin was an appropriate replacement for beta carotene in AREDS2 supplements. Beta carotene usage nearly doubled the risk of lung cancer, whereas there was no statistically significant increased risk with lutein/zeaxanthin. When compared with beta carotene, lutein/zeaxanthin had a potential beneficial association with late AMD progression.

来源:JAMA Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Chew EY, Clemons TE, Agrón E, et al. Long-term Outcomes of Adding Lutein/Zeaxanthin and ω-3 Fatty Acids to the AREDS Supplements on Age-Related Macular Degeneration Progression: AREDS2 Report 28. JAMA Ophthalmol. 2022. PMID: 35653117. doi:10.1001/jamaophthalmol.2022.1640

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。